Specialist Electromedical Clothes

Model: IONCO-IQ3

- Helmet

- Vest

- Trousers


Commencement of the therapy

We start the therapy with a 15-minute application. We make at least 2-hour intervals between individual applications. Further procedure in line with the scheme presented in the table below.

Table of the ECCT-TTF applications

Selection of an application duration

When increasing the duration of an individual application, some symptoms of discomfort may occur, and that is why we select optimal duration of the application from the table. 


An optimal one-day application was selected

Number of applications:                               4 times a day

Duration of an application                           60 minutes

Intervals between applications:                   at least 2 hours 

We may select from Two Therapeutic Schemes, which, in order to increase therapeutic activity, may be used interchangeably.

The First Therapeutic Scheme - Cycle 5/2 


The Second Therapeutic Scheme - Cycle 2/1



Preparation for the ECCT-TTF Therapy

Proper hydration of the body.

Do not use on an empty stomach.

Before the therapy the patient should have a small protein meal + Vit C tabl. (soluble, 1,000 mg adults, children proportionally smaller amount).

During the application one should wear well-isolated shoes (with rubber soles) in case of contact with surfaces like concrete, floor, etc.

During the ECCT-TTF therapy one should not use therapies like acupressure,
acupuncture and physical therapy treatments.


The signs of discomfort that may occur during the ECCT-TTF Therapy  

Increased excretion (urine, sweat, stool) and changes in colour,
smell and consistency may be observed.

Increased amount of gases may occur in the digestive system. All those signs are the result of the process of cancer mass elimination.


The signs of excess reaction that may occur during the ECCT-TTF Therapy are rare

The following symptoms of excess reaction of the body may occur: raised body temperature, nausea, muscular and articular pains, weakness. This is a reaction
to degradation of the cancer mass that is happening too fast.

In such a case we interrupt the therapy for a couple of days and then take it up according to the selected Therapeutic Scheme 5/2 or 2/1 and, as a preventive measure, consult our doctor. 


How long do we use the ECCT-TTF electrotherapy?

We use the ECCT-TTF electrotherapy from a few months to several years. Duration of the therapy depends on the size of tumour and the number of metastases
as well as the dynamics of the cancer.

The ECCT-TTF electrotherapy works fast and most effectively in the case of smaller, diffuse cancerous tumours. The bigger the cancer, the longer it gets to eliminate it from the patient's body.



Chemotherapy-CHT or Radiothreapy-RT are not contraindications for the ECCT-TTF therapy but, if it is possible, those therapies should not be used at the same time with the ECCT therapy, since the immune system is weakened.

It is best to wait for 2 - 3 weeks after the end of CHR and RT. However, the final decision depends on individual patient's status and their clinical condition.


Local hyperthermia 13.56 MHz (Oncotherm) may be used in conjunction with
the ECCT-TTF therapy.

Intravenous oxygen therapy (Oxyven) may also be used in conjunction with
the ECCT-TTF therapy.

Intravenous laser therapy (Weber Endolaser) may also be used in conjunction with
the ECCT-TTF therapy.


Periodic control of effectiveness of the ECCT-TTF electrotherapy

Before commencing the ECCT therapy the patient should undergo basic laboratory and diagnostic tests that are necessary to define their capacity and clinical condition (primary tumour, metastases, dynamics of the disease). This applies
to such basic test as:

Blood count, urinalysis, liver, kidney and heart values, ECG. Diagnostic tests for lyme disease are recommended. 

Tumour markers, LDH levels.

Follow-up ultrasound examinations, X-ray scans, MRI, PET, etc.

The mentioned examinations are normally performed during oncologic consultations. 


The ECCT-TTF Electrotherapy is an adjuvant therapy and in no way
does it substitute the basic oncologic therapy. However, this method
has a scientifically documented mechanism of action, thanks to which
disturbances in cell division process take place.